1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Senate, House Panels Release Clean Device User-Fee Discussion Draft

 
• By Sue Darcey

Lawmakers emphasized the need for a swift reauthorization of a combined US FDA device and drug user-fee reauthorization bill before the end of July, and released a clean discussion draft April 14 that mirrors the agreements reached by industry and the agency last summer.

Leaders of key Senate and House committees released a no-surprises, clean discussion draft to reauthorize US FDA user fees for devices and drugs April 14, emphasizing to members of Congress the need to swiftly reauthorize user fees based on the provisions previously agreed upon between industry and the agency that are contained in the bill. The device industry and FDA laid out the elements for the fourth iteration of user fees for the industry (MDUFA IV), including $999.5m in pre-inflation fees to be paid between FYs 2018 and 2022, last August.

The FDA Reauthorization Act of 2017 includes the features of the MDUFA IV agreement that require statutory changes, including the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

German Medtechs Choking Under EU Compliance And Reporting Obligations Tout Mutual Recognition

 
• By Ashley Yeo

Industry survey points to ongoing low revenues rise and weaker profit levels for half of BVMed industry association members in 2025, as German manufacturers raise stakes on global harmonization.

Fixing The Fractures: New Aspirations For EU Medtech Regulatory Progress

 
• By Amanda Maxwell

A pioneering initiative, Edvance MedTech, is being launched by leading experts in medical technology regulation which aims get to the heart of what is needed to improve the way EU rules are not only applied but also decided.

MedTech Innovator Winner Armor Medical Hopes To Reduce 90% Of Preventable Maternal Deaths

 
• By Marion Webb

Armor Medical’s wrist-worn wearable detected postpartum hemorrhage five times earlier than standard care in earlier studies. After surviving near-fatal hemorrhage herself, co-founder/CEO Kelsey Mayo aims to bring the device to market in 2028.